Nov. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Market and Product Forecasts: Melanoma – Yervoy will continue to dominate as new approvals struggle to compete
The melanoma market has seen an increase in developer attention following significant breakthroughs in treatment. New approvals have raised the bar to enter the market, but with drug resistance and toxicity still major problems, there are opportunities for developers to move into this market. The entry of pipeline drugs into the market will significantly increase the value of branded sales.
Analysis of melanoma drugs in the US and five major EU markets.
Patient-based sales forecast for drugs in the branded melanoma market from 2012 to 2021.
In-depth analysis of the factors influencing the melanoma market in individual countries.
Molecule dynamics and assessment of the key melanoma drugs in the US and five major EU markets.
The branded melanoma market in the US and five major EU markets (
Spain, and the UK) will experience significant growth over the forecast period. Sales revenue will increase from
$1.1bn in 2012 to just under
$2.4bn by 2021, demonstrating a compound annual growth rate (CAGR) of 9.24%.
Datamonitor estimates that in 2012 the US melanoma market will be worth
$691m, commanding 64% of the six surveyed markets total. Over the forecast period, the value of this market will increase to
$1.6bn, demonstrating a CAGR of 10.04%.
Yervoy is currently the highest grossing melanoma drug in the US and the five major EU markets, generating 2011 sales of
$360m. Few pipeline drugs are expected to actively compete with Yervoy over the forecast period, and Yervoy is forecast to generate sales of over
$1bn by 2021.
Quantify the performance of each of melanoma drug in the US and five major EU markets by sales and patient numbers.
Gain insight into the key trends in individual melanoma markets across the US and five major EU markets.
The report is accompanied by a PowerPoint presentation and Excel deliverable showing full melanoma forecasts for each country
•Strategic scoping and focus•Datamonitor key findings
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts